Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA
- PMID: 8551607
- PMCID: PMC189871
- DOI: 10.1128/JVI.70.2.712-720.1996
Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA
Abstract
We have compared the effects of nucleoside analogs in quiescent and phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMC) exposed to human immunodeficiency virus type 1 (HIV-1) with those of their triphosphorylated derivatives in cell-free HIV-1 reverse transcription assays. We observed a substantial decrease in synthesis of early minus-strand proviral DNA products in HIV-1-infected, quiescent PBMC exposed to each of 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (ddI), and 2',3'-dideoxy-3'-thiacytidine (3TC), in comparison with nontreated, infected controls. In contrast, no such diminution was observed when PHA-stimulated, HIV-1-infected PBMC were treated with the same drugs. This result was attributed to previously reported findings that PHA-stimulated PBMC possessed larger deoxynucleoside triphosphate (dNTP) pools than quiescent cells did. To further investigate this subject, a cell-free HIV-1 reverse transcription reaction involving HIV-1 RNA genomic template, recombinant purified HIV-1 reverse transcriptase, all four dNTPs and either tRNA3Lys or a deoxyoligonucleotide as primer was used to monitor chain termi-nation mediated by 2',3'-dideoxynucleoside triphosphates (ddNTPs) during synthesis of minus-strand strong-stop DNA. Augmented chain termination was observed with decreasing concentrations of both ddNTP and dNTP when the ratio of dNTP to ddNTP was fixed. We also found that both the number and strength of reverse transcription pause sites were increased at low concentrations of dNTPs and when a deoxyoligonucleotide primer was used in place of the cognate primer, tRNA3Lys. Preferential incorporation of ddATP was observed dur-ing reverse transcription opposite a distinct pause site in a short synthetic RNA template. These results con-firm the notion that the antiviral activities of ddNTP are dependent on both cellular dNTP pools and the state of cellular activation. Pausing of HIV-1 reverse transcriptase during reverse transcription, altered by dNTP concentrations, may be a mechanism that controls the position and extent of incorporation of nucleoside analogs.
Similar articles
-
Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription.Antimicrob Agents Chemother. 1994 May;38(5):1008-16. doi: 10.1128/AAC.38.5.1008. Antimicrob Agents Chemother. 1994. PMID: 7915097 Free PMC article.
-
Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site.J Biol Chem. 2000 Jan 7;275(1):359-66. doi: 10.1074/jbc.275.1.359. J Biol Chem. 2000. PMID: 10617626
-
The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.J Biol Chem. 1994 Nov 11;269(45):28118-22. J Biol Chem. 1994. PMID: 7525567
-
Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.Biochim Biophys Acta. 2002 Jul 18;1587(2-3):296-9. doi: 10.1016/s0925-4439(02)00092-3. Biochim Biophys Acta. 2002. PMID: 12084471 Review.
-
Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.Antivir Ther. 2001;6 Suppl 3:25-44. Antivir Ther. 2001. PMID: 11678471 Review.
Cited by
-
Targets of small interfering RNA restriction during human immunodeficiency virus type 1 replication.J Virol. 2008 Mar;82(6):2938-51. doi: 10.1128/JVI.02126-07. Epub 2008 Jan 16. J Virol. 2008. PMID: 18199654 Free PMC article.
-
Influence of sequence identity and unique breakpoints on the frequency of intersubtype HIV-1 recombination.Retrovirology. 2006 Dec 12;3:91. doi: 10.1186/1742-4690-3-91. Retrovirology. 2006. PMID: 17164002 Free PMC article.
-
Genital Immune Cell Activation and Tenofovir Gel Efficacy: A Case-Control Study.Clin Infect Dis. 2022 Sep 29;75(6):1088-1091. doi: 10.1093/cid/ciac115. Clin Infect Dis. 2022. PMID: 35142337 Free PMC article.
-
Weekly Oral Tenofovir Alafenamide Protects Macaques from Vaginal and Rectal Simian HIV Infection.Pharmaceutics. 2024 Mar 11;16(3):384. doi: 10.3390/pharmaceutics16030384. Pharmaceutics. 2024. PMID: 38543278 Free PMC article.
-
The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.Antiviral Res. 2021 Feb;186:105001. doi: 10.1016/j.antiviral.2020.105001. Epub 2020 Dec 29. Antiviral Res. 2021. PMID: 33385420 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources